LAVA Therapeutics (NASDAQ:LVTX) Releases Earnings Results

LAVA Therapeutics (NASDAQ:LVTX) announced its quarterly earnings data on Friday. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.18, Zacks reports. The firm had revenue of $2.50 million for the quarter, compared to analyst estimates of $2.40 million.

LAVA Therapeutics Price Performance

Shares of LVTX traded down $0.01 during midday trading on Friday, hitting $1.29. The stock had a trading volume of 43,333 shares, compared to its average volume of 173,459. The firm has a market cap of $33.92 million, a price-to-earnings ratio of -1.25 and a beta of 0.48. The company has a 50 day simple moving average of $1.13 and a two-hundred day simple moving average of $1.37. LAVA Therapeutics has a twelve month low of $0.85 and a twelve month high of $3.57.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. HC Wainwright restated a “neutral” rating and set a $1.50 price target (down previously from $2.00) on shares of LAVA Therapeutics in a research note on Thursday, February 27th. JMP Securities reaffirmed a “market perform” rating and set a $6.00 price objective on shares of LAVA Therapeutics in a report on Wednesday, December 11th. Citizens Jmp cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Leerink Partnrs downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $2.00 target price (down from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat, LAVA Therapeutics has an average rating of “Hold” and an average target price of $3.17.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.